|
Screening of 129 FDA approved anti-cancer drugs in colorectal cancer cell lines resistant to oxaliplatin or irinotecan (SN38). |
|
|
No Relationships to Disclose |
|
Christine Hjorth Andreassen |
No Relationships to Disclose |
|
|
Employment - Medical Prognosis Institute; Oncology Venture; WntResearch |
Leadership - Medical Prognosis Institute; Oncology Venture; WntResearch |
Stock and Other Ownership Interests - Medical Prognosis Institute; Oncology Venture; WntResearch |
Honoraria - Medical Prognosis Institute; Oncology Venture; WntResearch |
Consulting or Advisory Role - Medical Prognosis Institute; Oncology Venture; WntResearch |
Research Funding - Medical Prognosis Institute (Inst); Oncology Venture (Inst); WntResearch (Inst) |
Patents, Royalties, Other Intellectual Property - Saniona A/S |
Travel, Accommodations, Expenses - Medical Prognosis Institute; Oncology Venture; WntResearch |